Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02892305 · ClinicalTrials.gov registry record
Hepatic Resection for Metastatic Pancreatic Cancer
A clinical trial of Neoplasm Metastasis and Pancreatic Neoplasms, sponsored by Duke University.
- Active
- Registry status
- 18
- Enrollment target
- 1
- Study location
NCT02892305: Active study of Neoplasm Metastasis and Pancreatic Neoplasms, sponsored by Duke University.
NCT02892305 is a study of Neoplasm Metastasis and Pancreatic Neoplasms that is active but no longer recruiting, run by Duke University. The registered enrollment target is 18 participants, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02892305, a study of Neoplasm Metastasis and Pancreatic Neoplasms, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM). We will evaluate and describe the surgical and overall outcomes of an initial cohort of subjects who undergo pancreatectomy and hepatic resection/ablation for PAC with LVHM. The end of study results will be reviewed by the Hepatiobiliary Multidisciplinary Conference (HDMC) and Surgery Audit Committee (SAC) to determine the appropriateness of adding this treatment arm for patients with oligometastatic metastatic pancreatic cancer.
Primary Outcome
Number of deaths within 90 days of operation
Conditions Studied
Interventions
- PROCEDURE Hepatic Resection or Ablation with Pancreaticoduodenectomy
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-05-18 |
| Est. Completion | 2027-06-30 |
What the registry record for NCT02892305 still lists
NCT02892305 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 1 intervention - of which Hepatic Resection or Ablation with Pancreaticoduodenectomy is the first listed.
NCT02892305 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02892305 about?
NCT02892305 is a clinical study titled "Hepatic Resection for Metastatic Pancreatic Cancer". The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM). We will evaluate and describe the surgical and overall outcomes of an initial cohort of subjects ...
What is the current status of trial NCT02892305?
This trial is currently active not recruiting. The enrollment target is 18 participants. The study started on 2018-05-18. Estimated completion is 2027-06-30.
What conditions does trial NCT02892305 study?
This clinical trial studies the following conditions: Neoplasm Metastasis, Pancreatic Neoplasms, Liver Metastases.
What interventions are being tested in trial NCT02892305?
The interventions under investigation include: Hepatic Resection or Ablation with Pancreaticoduodenectomy (PROCEDURE).
Who is sponsoring clinical trial NCT02892305?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02892305 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02892305's enrollment target sits among peer trials
18 39th of 41 higher than 3 of 41 other Neoplasm Metastasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasm Metastasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
RECRUITING · NA
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI